Stereotaxis CEO David Fischel discussed the company’s expansion into PFA on an earnings call in March. Fischel said Stereotaxis’ focus on complex arrhythmias was largely shielding the business from changes unleashed by the launch of PFA devices. Stereotaxis’ device is designed to enable procedures that would be “very difficult to be done successfully, safely or at all” without robotics, Fischel said.

Yet the market dynamics “are distracting for our customers,” the CEO said, and having a PFA system will help Stereotaxis meet its clients’ long-term goals. Stereotaxis’ desire to develop a PFA system has led to the CardioFocus agreement.